Company Page
Most Recent Insiders Activity
| Transaction Date | Company Name | Insider Name (Title) | Activity | Stock | Acquired or Disposed | Shares | Price range | Amount |
|---|---|---|---|---|---|---|---|---|
| 2024-11-05 | Janux Therapeutics, Inc. | Gujrathi Sheila
(Director) |
J | Common Stock | A | 4611 | $0.00 - $0.00 | $0 |
| 2024-11-05 | Janux Therapeutics, Inc. | CAPPS VICKIE L
(Director) |
J | Common Stock | A | 2305 | $0.00 - $0.00 | $0 |
| 2024-10-28 | Janux Therapeutics, Inc. | Campbell David Alan
(President and CEO) |
S | Common Stock | D | 25000 | $53.22 - $53.94 | $1,338,558 |
| 2024-09-13 | Janux Therapeutics, Inc. | Lichter Jay
(AtLeastTenPercentOwner) |
S | Common Stock | D | 3815 | $46.68 - $46.68 | $178,084 |
| 2024-09-13 | Janux Therapeutics, Inc. | Lichter Jay
(AtLeastTenPercentOwner) |
M | Common Stock | A | 3815 | $10.73 - $39.80 | $65,949 |
| 2024-10-18 | Janux Therapeutics, Inc. | Shah Rajeev M.
(Director) |
P | Common Stock | A | 1200000 | $44.75 - $44.75 | $53,700,000 |
| 2024-10-16 | Janux Therapeutics, Inc. | Lichter Jay
(AtLeastTenPercentOwner) |
S | Common Stock | D | 1673128 | $44.75 - $51.18 | $77,472,365 |
| 2024-10-16 | Janux Therapeutics, Inc. | Lichter Jay
(AtLeastTenPercentOwner) |
M | Common Stock | A | 12284 | $10.73 - $39.80 | $222,008 |
| 2024-09-26 | Janux Therapeutics, Inc. | Lichter Jay
(AtLeastTenPercentOwner) |
S | Common Stock | D | 307779 | $46.19 - $47.77 | $14,452,386 |
| 2024-09-27 | Janux Therapeutics, Inc. | Lichter Jay
(AtLeastTenPercentOwner) |
M | Common Stock | A | 2671 | $10.73 - $39.80 | $48,257 |
| 2024-09-27 | Janux Therapeutics, Inc. | Meyer Andrew Hollman
(Chief Business Officer) |
S | Common Stock | D | 50000 | $45.96 - $45.96 | $2,297,755 |
| 2024-09-27 | Janux Therapeutics, Inc. | Meyer Andrew Hollman
(Chief Business Officer) |
M | Common Stock | A | 50000 | $4.21 - $4.21 | $210,500 |
| 2024-09-27 | Janux Therapeutics, Inc. | DiRaimondo Thomas
(Chief Scientific Officer) |
S | Common Stock | D | 5000 | $46.21 - $47.22 | $231,715 |
| 2024-09-27 | Janux Therapeutics, Inc. | Campbell David Alan
(President and CEO) |
S | Common Stock | D | 25000 | $46.09 - $47.84 | $1,157,640 |
| 2024-09-10 | Janux Therapeutics, Inc. | Lichter Jay
(AtLeastTenPercentOwner) |
S | Common Stock | D | 451091 | $46.13 - $47.00 | $21,153,618 |
| 2024-07-19 | Janux Therapeutics, Inc. | DOBMEIER ERIC
(Director) |
A | Common Stock | A | 1231 | $0.00 - $0.00 | $0 |
| 2024-07-19 | Janux Therapeutics, Inc. | Hernday Natasha
(Director) |
A | Common Stock | A | 1231 | $0.00 - $0.00 | $0 |
| 2024-07-19 | Janux Therapeutics, Inc. | DOBMEIER ERIC
(Director) |
A | Common Stock | A | 7500 | $0.00 - $0.00 | $0 |
| 2024-07-19 | Janux Therapeutics, Inc. | Hernday Natasha
(Director) |
A | Common Stock | A | 7500 | $0.00 - $0.00 | $0 |
| 2024-06-26 | Janux Therapeutics, Inc. | Shah Rajeev M.
(Director) |
A | Common Stock | A | 2500 | $0.00 - $0.00 | $0 |
| 2024-06-03 | Janux Therapeutics, Inc. | Lichter Jay
(Director) |
S | Common Stock | D | 1500000 | $54.75 - $54.75 | $82,124,999 |
| 2024-06-03 | Janux Therapeutics, Inc. | Reardon Tighe
(Acting Chief Financial Officer) |
S | Common Stock | D | 822721 | $54.75 - $54.75 | $45,043,974 |
| 2024-06-03 | Janux Therapeutics, Inc. | Avalon BioVenture...
(AtLeastTenPercentOwner) |
S | Common Stock | D | 1500000 | $54.75 - $54.75 | $82,124,999 |
Activity types
| A | Grant, award or other acquisition |
| C | Conversion of Derivative or Security |
| D | Disposition to the issuer of issuer equity securities |
| E | Expiration of short derivative position |
| F | Payment of exercise price or tax liability |
| G | Bona fide Gift |
| H | Expiration (or cancellation) of long derivative position with value received |
| I | Discretionary Transaction |
| J | Other acquisition or disposition |
| K | Transaction in equity swap or instrument with similar characteristics |
| L | Small Acquisition |
| M | Exercise or conversion of derivative security |
| O | Exercise of out-of-the-money derivative security |
| P | Open Market Purchase |
| S | Open Market Sale |
| U | Disposition pursuant to a tender of shares in a change of control transaction |
| V | Transaction Voluntarily Reported |
| X | Exercise of in-the-money or at-the-money derivative security |
| Z | Deposit into or withdrawal from voting trust |